SAB BiotherapeuticsSABS
Recorded

SAB Biotherapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration22 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hi, everyone. Thank you so much for joining us at the Jefferies London Conference. My name is Cha Cha Yang. I am a Senior Associate working with Roger Song, my analyst in the Boston office. We cover mid-cap biotech, and it is my pleasure today to welcome Pleasure to be here.

Operator

Sam, maybe we do a high-level introduction for SAB BIO first. Can you just tell us what you guys have accomplished in the last year and what you are looking forward to in 2027?

Sam ReichCEO

Yes. SAB BIO is a clinical-stage biopharmaceutical company. We are in a pivotal study for the treatment of type 1 diabetes, and we have a proprietary drug, which is a human anti-thymocyte immunoglobulin or thymocyte-targeting plasma-derived IgG. We are currently in a pivotal study, which should be completing enrollment this month.

Operator

Okay, that's very exciting. There's been a lot of increasing spotlight on the T1D space over the last few years, and you guys are specifically focused on that. With a lot of approvals and new innovative data coming out in this space, with your experience at SAB, can you just speak more to how you have seen this disease space evolve, and whether that be from investors, from pharma, patient communities, the excitement in this space that's coming up?

Sam ReichCEO

Yes. For many years, a lot of the innovation was around insulin delivery and glucose monitoring, which certainly sort of increased the convenience for the patient. There has been a lot of attention and excitement around islet cell transplant, which is really today a late-stage therapy for patients that have lost all their ability to make their own insulin. Recently, over the last couple of years, there's been more and more focus on first-line treatment for new patients to preserve their ability to make insulin, and that's through immunomodulation. The doctors and the experts, and we've complied with the drug companies, have come to realize that our first obligation for type 1 diabetes patients is to preserve their ability to make insulin.

Sam ReichCEO

Like with any autoimmune disease, when you recognize that a patient is not tolerant to a key organ, our goal is to save that organ. Tzield was approved, the first immunomodulator, in June of this year, and now there's an approved therapy to preserve the patient's ability to make insulin, which is doing a lot to educate the medical community and get awareness around there, around the importance of preserving insulin production. We're following close behind with what we believe is a superior product for preservation of the patient's ability to make their own insulin.

Operator

Yeah, so you mentioned Tzield, which was an exciting approval. There are a couple other companies that are making these immunomodulators. Can you speak more to how SAB-142 is different from these approaches?

Sam ReichCEO

Yes. Tzield, which is the only approved drug, is a monoclonal antibody targeting T cells, and it has shown the ability to preserve C-peptide, which is the key marker for a patient's endogenous insulin production. To date, in clinical trials, it has only shown the ability to preserve C-peptide, but it has not shown clinical endpoints such as HbA1c or insulin use. It also requires 12 days of continuous dosing. Our drug, the human IgG or human anti-thymocyte immunoglobulin, based on the data that we have to date from our own drug and a reference product, is two-day dosing. There's evidence that the drug should reduce HbA1c, a functional or clinical marker, and it's a drug that can be redosed for the life of the patient to continue to provide therapy to maintain insulin production.

Operator

You guys are in phase IIb right now, and you have your top-line data coming out in 2027. Can you tell us more about your primary endpoint that you're testing and what the benchmarks for success will look like? More specifically, we'd love to learn more about the historical data that drove your powering assumptions, so if you could speak more to that.

Sam ReichCEO

Sure. In this field of immunomodulation for newly diagnosed patients, the primary endpoint, which is really the measure of your drug doing the job, is C-peptide, and we're looking to preserve C-peptide compared to placebo. That's the sign of efficacy in a drug. C-peptide is the measure of endogenous insulin production. The key secondary endpoints are HbA1c, which shows that with that benefit of preserved C-peptide, the patient has better glycemic control, which is meaningful to the patient and the doctor. Sorry, can you just do the part B and C? I forgot. Oh, yeah. the question.

Operator

Really just about benchmarks and also more so about, like, what are your historical- Right.

Sam ReichCEO

So for benchmarks, Tzield, the approved drug, has shown preservation of C-peptide, but has not shown efficacy or hitting any secondary endpoints. They have not reduced HbA1c, or they haven't shown it. They haven't reduced insulin use. They haven't reduced, or they haven't improved glycemic control as measured by time in range. And we believe we have the ability to do that based on these historical benchmarks. An important foundation for our program is a drug with the same mechanism of action, which is called Thymoglobulin. It's a commercial product for organ transplant. It's sold by Sanofi, and it has been shown to both preserve C-peptide and reduce HbA1c. In the same patient population, in two different clinical trials, randomized double-blinded clinical trials. One is called TN19 and one is called MELD-ATG. Now, that drug, Thymoglobulin, is made in rabbits, and it is a rabbit-derived anti-thymocyte globulin.

Sam ReichCEO

Because it is rabbit protein or rabbit IgG, it is highly immunogenic, which leads to serum sickness and AE, which is really undesirable, and it can't be redosed. So it's a one and done. You can't get that drug twice, and this is a chronic disease. Our drug is the same type of drug, but it's fully human, and we've already shown in phase I it is not immunogenic and it does not cause serum sickness. So we believe we can rely on the efficacy as seen with Thymoglobulin, and we've already shown that we have the advantages needed for a good target product profile, which is redosability and no serum sickness.

Sam ReichCEO

Now, our clinical trial design was modeled after one of these studies, which was called TN19, in which we had all of the data given to us with permission, and were able to use the variability and the patient inclusion and exclusion criteria to design the study. We designed effectively the same study and powered accordingly as the Thymoglobulin study, which showed both preservation of C-peptide as well as HbA1c, giving us high confidence in our likelihood of success.

Operator

That is really exciting. We have talked a little bit about the convenience factor. We talked about the efficacy you are looking at. Can you just tell us more about the safety data that you are expecting to see, and are there any AEs that we should be on the lookout for?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day